Continuous manufacturing pharmaceutical systems merge blending, granulation, and compression into one unbroken line to meet GMP compliance under 21 CFR Part 11. These lines run in-line, real-time quality monitoring instead of end-of-batch testing, typically handling 5 to 40 kg per hour. Canaan’s integrated pharmaceutical continuous manufacturing lines are built to meet these standards, combining feeding, granulation, and compression in one GMP-ready platform.
A continuous line feeds raw powder in at one end and discharges finished tablets at the other, without stopping between steps. Loss-in-weight feeders meter each ingredient by mass flow rather than by container.
Material then moves through a granulator, a dryer, and a tablet press in one connected sequence. Sensors along the line record blend uniformity and particle size as the run happens, not after it finishes.
Feeders and blenders in a continuous train are compact by design, often built to run 5 to 40 kg per hour. That range covers early development batches and mid-scale commercial runs without swapping equipment.
Because feeding and blending happen in one enclosed loop, operators handle fewer manual transfers, and each removed transfer point is one less contamination risk.
Compression is the last mechanical step before a tablet leaves the line. Some integrated platforms connect upstream processing equipment with a rotary tablet press as part of the overall production train. Depending on the formulation, the upstream process may use direct blending or include granulation and drying before compression.
GMP compliance on a continuous line depends on process analytical technology (PAT) working alongside electronic records that meet 21 CFR Part 11.
Continuous manufacturing still uses defined batch and material-tracking approaches. Product quality is demonstrated through the validated process, control strategy, monitoring, testing, and quality system.
FDA Q13 confirms that continuous manufacturing still uses the concept of a batch. A batch may be defined by output quantity, input quantity, or production time at specified mass flow rates. Material tracking and process controls identify the material included in each batch and support quality decisions.
21 CFR Part 11 applies to qualifying electronic records based on their regulatory use, not on whether manufacturing is batch or continuous.
| Compliance Element | Batch Manufacturing | Continuous Manufacturing |
| Sampling method | May use in-process and end-product sampling, depending on the control strategy | May use in-line, online, at-line, or offline monitoring and testing |
| Record type | May include paper, electronic, or hybrid records | May generate more frequent or continuous process data alongside required production records |
| Part 11 scope | Depends on which regulated records are maintained or submitted electronically | The same principle applies; scope is determined by the electronic records and predicate-rule requirements, not the production mode |
| Deviation response | Can be identified during processing or during later review | Continuous monitoring may support faster detection and response to process disturbances |
Real-time release testing can use validated process data and measurements to evaluate certain quality attributes without relying solely on conventional end-product testing.
However, its use depends on the approved control strategy, analytical methods, process understanding, and supporting quality system. It does not mean that every sensor reading or feeder adjustment automatically becomes a Part 11 audit-trail record.
This is rarely an either-or decision. Many manufacturers run continuous lines for high-volume, stable formulations, while keeping batch equipment for smaller runs or products still in development.
Continuous tends to win where demand stays steady enough to run without frequent changeover. Batch still suits low-volume products, or formulations not yet stable for continuous processing.
The first step is not buying a full line. Most manufacturers start with a feasibility study on a small-scale unit, running the existing formulation through it before committing capital to a commercial system.
That study should track particle flow, blend uniformity, and feeder accuracy against existing specifications. Only after those numbers hold steady does a pilot line make sense.
No. Compact, small-scale units paired with a modest PAT package let a mid-size plant test the process without the outlay of a full commercial line. The compliance scope also stays smaller during the transition.
Canaan is the first company in solid dosage equipment manufacturing to be listed on the A-share market, built on decades inside China’s pharmaceutical equipment industry. That history shapes how its continuous lines are engineered for throughput and audit-readiness alike.
Canaan’s integrated platforms connect feeding, granulation, and compression in one frame, scaling from lab-level development up to commercial batches. Control software is built to support 21 CFR Part 11 record-keeping. These systems serve generic, branded, and nutraceutical oral solid dose manufacturers, where throughput and documented compliance carry equal weight.
Readers evaluating a batch-to-continuous move can review Canaan’s continuous manufacturing system coverage and its R&D tablet press design notes, or browse Canaan’s product range for pilot-scale options.
Batch processes fixed lots with testing after each step. Pharmaceutical continuous manufacturing runs one process with in-line monitoring, so quality data is collected during production, not after.
No. Small-scale units exist for development and pilot work, letting mid-size manufacturers test a formulation before a commercial-scale investment.
The rule itself does not change, but continuous lines generate more electronic data, so audit trails and access controls must cover a continuous stream rather than isolated records.
Ranges vary, but many compact systems handle roughly 5 to 40 kg per hour, covering development-scale runs and moderate commercial production.
Run a feasibility study on a small-scale unit with your current formulation, and confirm blend uniformity before planning a pilot line.
Quick Answer Continuous manufacturing pharmaceutical systems merge blending, granulation, and compression into one unbroken line to meet GMP compliance under 21 CFR Part 11. These lines run in-line, real-time quality monitoring instead of end-of-batch testing, typically handling 5 to 40 kg per hour. Canaan’s integrated pharmaceutical continuous manufacturing lines are built to meet these standards, […]
Quick Answer Cleaning validation in pharmaceutical manufacturing is the documented proof that equipment meets a set residue limit every time. A validated wash runs pre-rinse, detergent wash, rinse, and dry stages under fixed time, temperature, and pressure parameters. Canaan’s QD Series washing stations combine automated washing and drying in one controlled cycle, with key process […]
Quick Answer A CIP system cleans fixed pharmaceutical equipment, such as coating machines and fluid-bed dryers, by circulating water and cleaning solution through the system without disassembly. Programmed pressure, temperature, and cycle times help keep each cleaning run consistent. Canaan uses built-in CIP for fixed equipment and QD Series washing stations for bins and IBCs. […]
+86-577-67378828
canaan@chinacanaan.com